First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France

Key Points

• To describe the real-world use and safety of olaparib in combination with abiraterone for treating metastatic castration-resistant prostate cancer.
• Analyzed data from 154 patients enrolled in an early access program in France.
• Assessed patient characteristics in relation to those in the PROpel clinical trial.
• Evaluated safety signals and benefit-risk balance of the treatment.
• Patient characteristics were similar to those in the PROpel clinical trial.
• No new safety signals were identified in this real-world patient cohort.
• The overall benefit-risk balance of olaparib remained unchanged.

Abstract